Montes Archimedes Acquisition (ROIV)
(Real Time Quote from BATS)
$10.47 USD
0.00 (0.00%)
Updated Jun 10, 2024 11:26 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Roivant Sciences Ltd. [ROIV]
Reports for Purchase
Showing records 21 - 27 ( 27 total )
Company: Roivant Sciences Ltd.
Industry: Unclassified
Vtama''s Profile Should Drive Adoption; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Roivant Enters Patent Infringement Litigation Against Moderna Regarding LNPs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
On Track for Tapi Launch in Calendar 2Q22 and Details of Hemavant Revealed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Santa Comes Early With a Gift to Roivant as Appeals Court Rules in Favor of Arbutus and Roivant?s SNALP Patent; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Lots to Look Forward to for Tapi, ?1401, ?1801, and the Pipe in Catalyst-Rich 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Doc Survey Suggest Strong Uptake for Tapinarof, While Other Vants Offer Upside; Initiate With Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D